“The Buzz” Show: Alector, Inc. (NASDAQ: ALEC) Immuno-Neurology Development Collaboration With GSK | Financial Buzz“The Buzz'' Show: Alector, Inc. (NASDAQ: ALEC) Immuno-Neurology Development Collaboration With GSK

“The Buzz” Show: Alector, Inc. (NASDAQ: ALEC) Immuno-Neurology Development Collaboration With GSK

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Alector, Inc. Shares Climb Following Immuno-Neurology Development Collaboration With GSK”

Alector, Inc (NASDAQ: ALEC) surged over 39% in premarket trading after the company, alongside GlaxoSmithKline, announced a global collaboration in immuno-neurology for two clinical stage, first-in-class monoclonal antibodies for neurodegenerative diseases.

The collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s R&D focus on the science of the immune system and human genetics, and will focus on the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies designed to elevate progranulin levels.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs.

For more information, please visit: Alector, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!